Research Topics


The U4 Blog

Learning & events

About Us

Transparency in Covid-19 vaccine development and procurement 

Resource from others

Transparency in Covid-19 vaccine development and procurement 

This publication is from . Some of the content may be outdated. Search related topics to find more recent resources.

The 2021 Transparency International publication For whose benefit? Transparency in the development and procurement of Covid-19 vaccines analyses transparency issues across the development and subsequent buying of vaccines. Their research focuses on two key aspects of the Covid-19 vaccine value chain: clinical trials and procurement. In both areas, their analysis revealed a disturbing and dangerous lack of transparency. The report also ends with policy recommendations for WHO, the COVAX facility, national governments, drug regulatory agencies, vaccine developers, research institutions, international non-government organisations, and all public buyers of vaccines. 


    All views in this text are the author(s)’, and may differ from the U4 partner agencies’ policies.

    This work is licenced under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND 4.0)